{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T08:27:29Z","timestamp":1721896049543},"reference-count":27,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To find a more effective and less toxic chemotherapeutic agent, we have successfully prepared crystalline camptothecin-20(S)-O-propionate hydrate (CZ48) by reacting camptothecin with propionic anhydride using concentrated sulfuric acid as catalyst. The biological effectiveness of this new anticancer agent was evaluated by using xenografts of human cancers in nude mice as the testing models. The extensive treatment of 21 human tumors with various dose levels of CZ48 has shown that this agent is highly effective against many different human tumors tested with a striking lack of toxicity. Of the 21 human tumor lines tested, 9 regressed, 5 were &amp;lt;10% of the control, 3 were &amp;lt;20%, and 2 were &amp;lt;40%. Two tumors did not respond. The total response rate was 90% (19 of 21). No toxicity was observed in mice. The effective doses required to achieve the positive response varied from 100 to 1,000 mg\/kg\/d depending on the tumors. The maximum tolerated dose was not reached because of the nontoxic nature of the drug in mice. Thus, this compound has a much wider therapeutic index compared with that of the existing anticancer drugs currently in use. [Cancer Res 2009;69(11):4742\u20139]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-4452","type":"journal-article","created":{"date-parts":[[2009,5,20]],"date-time":"2009-05-20T02:49:14Z","timestamp":1242787754000},"page":"4742-4749","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Crystalline Camptothecin-20(<i>S<\/i>)-O-Propionate Hydrate:A Novel Anticancer Agent with Strong Activity against 19 Human Tumor Xenografts"],"prefix":"10.1158","volume":"69","author":[{"given":"Zhisong","family":"Cao","sequence":"first","affiliation":[{"name":"CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Kozielski","sequence":"additional","affiliation":[{"name":"CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[{"name":"CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Vardeman","sequence":"additional","affiliation":[{"name":"CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beppino","family":"Giovanella","sequence":"additional","affiliation":[{"name":"CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2009,6,1]]},"reference":[{"key":"2022061700284919200_B1","unstructured":"Van Kuilenburg ABP, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidinedehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res\u20082000; 6: 4705\u201312."},{"key":"2022061700284919200_B2","unstructured":"Van Kuilenburg ABP, Muller EW, Haasjes J, et al. Lethal outcome of a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G&gt;A mutation causing DPD deficiency. Clin Cancer Res\u20082001; 7: 1149\u201353."},{"key":"2022061700284919200_B3","unstructured":"DeVita VT, Hellman S, Rosenberg SA. Cancer, principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 335\u2013459."},{"key":"2022061700284919200_B4","doi-asserted-by":"crossref","unstructured":"Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer\u20081977; 39: 1357\u201361.","DOI":"10.1002\/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C"},{"key":"2022061700284919200_B5","doi-asserted-by":"crossref","unstructured":"Hayes D, Cvitkovic E, Golbey R, et al. High dose cis-platinum diamine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer\u20081977; 39: 1372\u201381.","DOI":"10.1002\/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J"},{"key":"2022061700284919200_B6","unstructured":"Evens B, Raju K, Calvert A, et al. Phase II study of JM8, a new platinum analogue, in advanced ovarian carcinoma. Cancer Treat Rep\u20081983; 67: 997\u20131000."},{"key":"2022061700284919200_B7","doi-asserted-by":"crossref","unstructured":"Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol\u20081997; 15: 2183\u201393.","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"2022061700284919200_B8","doi-asserted-by":"crossref","unstructured":"Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593\u2014a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol\u20082001; 19: 2114\u201322.","DOI":"10.1200\/JCO.2001.19.8.2114"},{"key":"2022061700284919200_B9","doi-asserted-by":"crossref","unstructured":"Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol\u20081999; 17: 658\u201367.","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"2022061700284919200_B10","doi-asserted-by":"crossref","unstructured":"Pizzolato JF, Saltz LB. The camptothecins. Lancet\u20082003; 361: 2235\u201342.","DOI":"10.1016\/S0140-6736(03)13780-4"},{"key":"2022061700284919200_B11","doi-asserted-by":"crossref","unstructured":"Miller AA, Lilenbaum RC, Lynch TJ, et al. Treatment-related fatal sepsis from topotecan\/cisplatin and topotecan\/paclitaxel. J Clin Oncol\u20081996; 14: 1964\u20135.","DOI":"10.1200\/JCO.1996.14.6.1964"},{"key":"2022061700284919200_B12","doi-asserted-by":"crossref","unstructured":"Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med\u20082002; 343: 905\u201314.","DOI":"10.1056\/NEJM200009283431302"},{"key":"2022061700284919200_B13","doi-asserted-by":"crossref","unstructured":"Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet\u20082000; 355: 1041\u20137.","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"2022061700284919200_B14","doi-asserted-by":"crossref","unstructured":"Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc\u20081966; 88: 3888\u201390.","DOI":"10.1021\/ja00968a057"},{"key":"2022061700284919200_B15","unstructured":"Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of anticancer drug camptothecin. Cancer Res\u20081988; 48: 1722\u20136."},{"key":"2022061700284919200_B16","unstructured":"Takimoto CH, Arbuck SG. Topoisomerase I targeting agents: the camptothecins. In: Chabner BA, Longo DL, editors. Cancer therapy and biotherapy: principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins 2001. p. 579."},{"key":"2022061700284919200_B17","doi-asserted-by":"crossref","unstructured":"Burke TG. Chemistry of the camptothecins in the bloodstream: drug stabilization and optimization of activity in the camptothecins\u2014from discovery to patients. Ann N Y Acad Sci\u20081993; 803: 29\u201331.","DOI":"10.1111\/j.1749-6632.1996.tb26373.x"},{"key":"2022061700284919200_B18","doi-asserted-by":"crossref","unstructured":"Mi z, Burke TG. Marked interspecies variations concerning interactions of camptothecin with serum albumin. Biochemistry\u20081994; 33: 1240\u20135.","DOI":"10.1021\/bi00208a002"},{"key":"2022061700284919200_B19","doi-asserted-by":"crossref","unstructured":"Giovanella BC, Stehlin JS, Wall ME, et al. Topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science\u20081989; 246: 1046\u20138.","DOI":"10.1126\/science.2555920"},{"key":"2022061700284919200_B20","unstructured":"Giovanella BC, Hinz HR, Kozielski AJ, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res\u20081991; 51: 3052\u20135."},{"key":"2022061700284919200_B21","doi-asserted-by":"crossref","unstructured":"Stehlin JS, Giovanella BC, Natelson EA, et al. A study of 9-nitrocamptothecin (RSF-2000) in patients with advanced pancreatic cancer. Int J Oncol\u20081999; 14: 821\u201332.","DOI":"10.3892\/ijo.14.5.821"},{"key":"2022061700284919200_B22","doi-asserted-by":"crossref","unstructured":"Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS. Dependence of antitumor activity of camptothecins on maintaining their lactone function. In: The camptothecins: unfolding their anticancer potential. Ann N Y Acad Sci\u20082000; 922: 27\u201335.","DOI":"10.1111\/j.1749-6632.2000.tb07022.x"},{"key":"2022061700284919200_B23","doi-asserted-by":"crossref","unstructured":"Cao Z, Harris N, Kozielski A, Vardeman D, Stehlin J, Giovanella B. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem\u20081998; 41: 31\u20137.","DOI":"10.1021\/jm9607562"},{"key":"2022061700284919200_B24","doi-asserted-by":"crossref","unstructured":"Cao Z, Mendoza J, DeJesus A, Giovanella B. Synthesis and antitumor activity of alkenyl camptothecin esters. Acta Pharmacol Sin\u20082005; 26: 235\u201341.","DOI":"10.1111\/j.1745-7254.2005.00031.x"},{"key":"2022061700284919200_B25","doi-asserted-by":"crossref","unstructured":"Cao Z, Pantazis P, Mendoza J et al. Structure-activity relationship of alkyl camptothecin esters. Ann N Y Acad Sci\u20082000; 922: 122\u201335.","DOI":"10.1111\/j.1749-6632.2000.tb07031.x"},{"key":"2022061700284919200_B26","unstructured":"Cao Z, Pantazis P, Mendoza J, at al. Structure-activity relationship of alkyl 9-nitrocamptothecin esters. Acta Pharmacol Sin\u20082003; 24: 109\u201319."},{"key":"2022061700284919200_B27","doi-asserted-by":"crossref","unstructured":"Lui X, Wang Y, Vardeman D, Cao Z, Giovanella B. Development and validation of a reverse-phase HPLC with fluorescence detector method for simultaneous determination of CZ48 and its active metabolite camptothecin in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci\u20082008; 867: 84\u20139.","DOI":"10.1016\/j.jchromb.2008.03.013"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/11\/4742\/2610034\/4742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/11\/4742\/2610034\/4742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:13:42Z","timestamp":1655442822000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/11\/4742\/549561\/Crystalline-Camptothecin-20-S-O-Propionate-Hydrate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,1]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,6,1]]},"published-print":{"date-parts":[[2009,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-4452","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,1]]}}}